News

In this episode, Dominic Sisti and Steve Levine discuss dilemmas surrounding donor transplants, brain death, and cardiac death in organ donations.

This episode highlights the recent technological advancements made by Medtronic Diabetes in treating type 1 and 2 diabetes.

Barratt describes the evolving diagnostic and therapeutic landscape of IgAN and breaks down key recommendations from the new KDIGO guidelines.

This review of the month of September highlights some of the most significant dermatology headlines.

Amgen announced that evolocumab reduced the risk of MACEs such as heart attack and stroke in patients without any prior history of these events.

This review of Q3 developments in the dermatology space highlight a number of significant news stories from 2025.

Explore the latest advancements in allergy and immunology, including new therapies, FDA approvals, and innovative clinical strategies for improved patient care from Q3.

Read about hepatic FDA news, the voluntary withdrawal of obeticholic acid for PBC, new trial data for a potential AATD drug, and more.

September 2025 saw 1 new approval, new long term data on smoking and emphysema, and more.

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Staller describes key takeaways from the 12 conditional recommendations made in the American Gastroenterological Association’s new gastroparesis guideline.

During this EADV interview, Lebwohl speaks to some of the most recent developments in the psoriasis research space.

This month in review features the latest breakthroughs in allergy treatments, including innovative therapies for cat and peanut allergies.

Check out renal FDA news, new KDIGO guidelines on IgAN and IgAV management, research about hypertensive kidney disease, and more.

This interview highlights the significance of remibrutinib's recent FDA approval for clinicians treating chronic spontaneous urticaria.

The first oral BTK inhibitor for CSU offers fast relief for patients uncontrolled on antihistamines and an alternative to injectable biologics.

The FDA has approved remibrutinib, a new oral treatment for chronic spontaneous urticaria, offering hope for patients unresponsive to antihistamines.

A study found 3% hypertonic saline nasal irrigation reduced symptoms in allergic rhinitis but offered no significant advantage over isotonic saline.

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This Savvy Stories episode of the Skin of Color Savvy podcast features 4 speakers highlighting the SOCS Clinical Investigators Training Program.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

In this Q&A, Malhotra discusses how tirzepatide impacts obstructive sleep apnea treatment.

Neuen is joined by Richard Pratley, MD, and Muthiah Vaduganathan, MD, MPH, to discuss the evolving landscape of CKM trial design.

New research highlights the benefits of PAP therapy for sleep apnea, showing improvements in blood pressure and cardiometabolic health.